Literature DB >> 8109296

Present-day indications for capsulotomy.

P Mindus1.   

Abstract

Although the majority of patients with anxiety disorders respond well to behavioural techniques of exposure and response prevention, to pharmacotherapy, or, more commonly, to combinations of the two approaches, a small percentage of patients remain refractory and are severely disabled by their symptoms. Some of these individuals constitute candidates for neurosurgical intervention, e.g. cingulotomy and capsulotomy. Therefore, such operations are performed, if to a very limited extent, both in the United States and in Europe to-day. At the Karolinska, patients are accepted for capsulotomy who suffer from chronic, severe, incapacitating, and otherwise intractable anxiety disorders, i.e. obsessive-compulsive disorder, generalized anxiety disorder and phobias. The present-day inclusion and exclusion criteria are described, and the safety and the efficacy of capsulotomy in these extreme forms of anxiety disorders are discussed.

Entities:  

Mesh:

Year:  1993        PMID: 8109296     DOI: 10.1007/978-3-7091-9297-9_6

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  4 in total

1.  Anterior capsulotomy for refractory OCD: First case as per the core group guidelines.

Authors:  Paresh K Doshi
Journal:  Indian J Psychiatry       Date:  2011-07       Impact factor: 1.759

2.  Deep brain stimulation of ventral internal capsule for refractory obsessive-compulsive disorder.

Authors:  Alok Gupta; Sumant Khanna; Rahul Jain
Journal:  Indian J Psychiatry       Date:  2019 Sep-Oct       Impact factor: 1.759

3.  "Getting physical": the management of neuropsychiatric disorders using novel physical treatments.

Authors:  Gin S Malhi; Colleen Loo; Catherine M Cahill; Jim Lagopoulos; Philip Mitchell; Perminder Sachdev
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

4.  Deep Brain Stimulation of Medial Dorsal and Ventral Anterior Nucleus of the Thalamus in OCD: A Retrospective Case Series.

Authors:  Mohammad Maarouf; Clemens Neudorfer; Faycal El Majdoub; Doris Lenartz; Jens Kuhn; Volker Sturm
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.